Form 4: Rapport Therapeutics Director James Healy Reports Beneficial Ownership Changes After IPO

Director James Healy reports changes in beneficial ownership of Rapport Therapeutics common stock following the company's initial public offering.

Summary

• James Healy, a director of Rapport Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock on June 10, 2024.
• The filing reflects the conversion of Series B Preferred Stock into Common Stock upon the closing of Rapport Therapeutics' IPO.
• Healy's indirect ownership includes shares held by Sofinnova Venture Partners XI, L.P., Sofinnova Synergy Master Fund LP, Crestline Summit Master, SPC CRESTLINE SUMMIT APEX SP, Crestline Summit Master, SPC PEAK SP, and CRESTLINE SUMMIT PINNACLE MASTER, L.P.
• He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
• The transactions include the conversion of 11,924,138 shares of Series B Preferred Stock into 1,392,738 shares of Common Stock.
• Additional purchases of common stock were made at $17 per share, increasing the indirect holdings.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing detailing ownership changes following an IPO. It doesn't contain inherently positive or negative information, but the successful IPO is a positive event.

Industry Context

Form 4 filings are standard practice following significant events like IPOs, providing transparency into insider ownership changes.

Stakeholder Impact

• Shareholders are informed about the ownership structure and changes following the IPO.
• The filing provides transparency to the market regarding insider transactions.

Key Dates